← Back to Search

Hormone Therapy

AZD9833 Combinations for Advanced Breast Cancer (SERENA-1 Trial)

Phase 1
Waitlist Available
Led By Richard Baird, MD PhD FRCP
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented positive oestrogen receptor status of primary or metastatic tumour tissue, according to the local laboratory parameters
HER-2 negative
Must not have
Uncontrolled hypertension
Intervention with any cytotoxic chemotherapy, investigational agents/other anti-cancer drugs for the treatment of advanced breast cancer within 14 days of the first dose of IMP
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug, AZD9833, to see if it can shrink tumors in women with a certain type of advanced breast cancer.

Who is the study for?
This trial is for women with advanced breast cancer that's ER positive and HER2 negative. They must be over 18, have had no more than two chemo treatments for advanced disease, and not be on certain drugs or have specific health issues like uncontrolled hypertension or severe systemic diseases. Participants need to agree to contraception if of childbearing potential.
What is being tested?
The study tests AZD9833 alone or combined with other drugs (capivasertib, abemaciclib, ribociclib, anastrozole, palbociclib, everolimus) in different groups to find the best treatment for this type of breast cancer. It's a Phase 1 trial focusing on dosage safety and effectiveness.
What are the potential side effects?
Potential side effects may include reactions related to hormone changes due to estrogen receptor targeting by AZD9833 and its combinations. Other risks could involve common drug-related side effects such as fatigue, nausea, risk of infection from low blood counts but specifics will depend on each drug combination.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is estrogen receptor positive.
Select...
My cancer is not HER2 positive.
Select...
My cancer has spread or returned and doesn't respond to current treatments.
Select...
My cancer has spread or returned and gotten worse after my last treatment.
Select...
I am not pregnant, not breastfeeding, and agree to use effective birth control.
Select...
I have at least one cancer lesion that can be monitored with scans or physical exams.
Select...
My condition allows for two tumor biopsies to be taken.
Select...
I am 18 years old or older.
Select...
My breast cancer is confirmed as adenocarcinoma.
Select...
I can care for myself and have not gotten worse in the past 2 weeks. My doctor thinks I have at least 3 months to live.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My blood pressure is not controlled by medication.
Select...
I haven't taken any cancer drugs or been in a trial for my advanced breast cancer in the last 14 days.
Select...
I haven't had major surgery or significant injury in the last 4 weeks and don't expect to need any during the study.
Select...
My cancer has spread to vital organs or the brain, and is not under control.
Select...
I am experiencing symptoms from lung inflammation caused by radiation.
Select...
My blood pressure is very low and not under control.
Select...
My blood tests show my bone marrow or organs aren't working well.
Select...
I am not taking medication that affects my heart's rhythm.
Select...
I do not have severe illnesses like uncontrolled high blood pressure, active bleeding disorders, or infections like hepatitis or HIV.
Select...
My heart's pumping ability is below normal, or I've had specific heart procedures or conditions in the last 6 months.
Select...
I have a history of interstitial lung disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The number of subjects with dose-limiting toxicity, as defined in the protocol.
The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.
Secondary study objectives
Area under the plasma concentration-time curve (AUC) for AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole
Assessment of biomarker changes
Clinical benefit rate at 24 weeks
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

14Treatment groups
Experimental Treatment
Group I: AZD9833 with ribociclib (± anastrozole) dose expansionExperimental Treatment1 Intervention
Group II: AZD9833 with ribociclib (± anastrozole) dose escalationExperimental Treatment1 Intervention
Group III: AZD9833 with palbociclib dose expansionExperimental Treatment1 Intervention
Group IV: AZD9833 with palbociclib dose escalationExperimental Treatment1 Intervention
Group V: AZD9833 with everolimus dose expansionExperimental Treatment1 Intervention
Group VI: AZD9833 with everolimus dose escalationExperimental Treatment1 Intervention
Group VII: AZD9833 with capivasertib dose expansionExperimental Treatment1 Intervention
Group VIII: AZD9833 with capivasertib dose escalationExperimental Treatment1 Intervention
Group IX: AZD9833 with anastrozole dose expansionExperimental Treatment1 Intervention
Group X: AZD9833 with anastrozole dose escalationExperimental Treatment1 Intervention
Group XI: AZD9833 with abemaciclib (± anastrozole)dose expansionExperimental Treatment1 Intervention
Group XII: AZD9833 with abemaciclib (± anastrozole) dose escalationExperimental Treatment1 Intervention
Group XIII: AZD9833 monotherapy dose expansionExperimental Treatment1 Intervention
Group XIV: AZD9833 monotherapy dose escalationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD9833 with everolimus
2021
Completed Phase 1
~30
AZD9833
2021
Completed Phase 2
~230
AZD9833 with palbociclib
2021
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,397 Previous Clinical Trials
289,121,260 Total Patients Enrolled
175 Trials studying Breast Cancer
1,243,071 Patients Enrolled for Breast Cancer
Richard Baird, MD PhD FRCPPrincipal InvestigatorBreast Cancer Research Unit, University of Cambridge
Justin Lindemann, MBChB MBAStudy DirectorAstraZeneca
1 Previous Clinical Trials
148 Total Patients Enrolled

Media Library

AZD9833 (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03616587 — Phase 1
Breast Cancer Research Study Groups: AZD9833 with ribociclib (± anastrozole) dose expansion, AZD9833 with anastrozole dose expansion, AZD9833 with capivasertib dose escalation, AZD9833 with abemaciclib (± anastrozole)dose expansion, AZD9833 with capivasertib dose expansion, AZD9833 with anastrozole dose escalation, AZD9833 with ribociclib (± anastrozole) dose escalation, AZD9833 with abemaciclib (± anastrozole) dose escalation, AZD9833 monotherapy dose escalation, AZD9833 monotherapy dose expansion, AZD9833 with palbociclib dose escalation, AZD9833 with palbociclib dose expansion, AZD9833 with everolimus dose expansion, AZD9833 with everolimus dose escalation
Breast Cancer Clinical Trial 2023: AZD9833 Highlights & Side Effects. Trial Name: NCT03616587 — Phase 1
AZD9833 (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03616587 — Phase 1
~56 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top